
WuXi Biologics' Profit Guidance Signals Rebound In China's Drug Sector
The provider of pharmaceutical services has joined other flagship companies in the WuXi group in projecting stronger first-half earnings after a couple of lean years Key Takeaways: WuXi Biologics expects first-half revenue to rise 16% and profit to jump …